Product Data Sheet

Cas No.:	300816-15-3	Cat. No:	PC10644
Product Name:	RS 504393		
Product synonym:	6 - 甲基-1,1' - [2 - (5 - 甲基- 2-苯基- 4-恶唑基)乙基] - 螺[4H - 3-1,1 - 苯并恶嗪- 4,4' -哌啶]-2(1H)-酮;6-甲基-1,1''-[2-(5-甲基-2-苯基-4-恶唑基)乙基]-螺[4H-3-1,1-苯;6-甲基-1,1''-[2-(5-甲基-2-苯基-4-恶唑基)乙基]-螺[4H-3-1,1-苯并恶嗪-4,4''-哌啶]-2(1H)-酮;6-甲基-1,1-[2-(5-甲基-2-苯基-4-恶唑基)乙基]-螺[4H-3-1,1-苯并恶嗪-4,4-哌啶]-2(1H)-酮;6-甲基-1'-[2-(5-甲基-2-苯基-4-恶唑基)乙基]螺[4H-3,1-苯并恶嗪-4,4'-哌啶]-2(1H)-酮;6-Methyl-1'-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)spiro-[benzo[d][1,3]oxazine-4,4'-piperidin]-2(1H)-one		
Chemical name:	RS 504393		
MF:	C25H27N3O3	FW:	417.5002
Purity:	≥98%	Batch No.:	-
Storage:			
Structural formula:			
λmax:	-	Formulation:	-
Solubility :			
SMILES :	O1C(N([H])C2C([H])=C([H])C(C([H])([H])[H])=C([H])C=2C21C([H])([H])C([H])([H])N(C([H])([H])C([H])([H])C1=C(C([H])([H])[H])OC(C3C([H])=C([H])C([H])=C([H])C=3[H])=N1)C([H])([H])C2([H])[H])=O		
InChI Code:	-		
InChI Key:			
WARNING This product is not for human or veterinary use.			

Product Description

CCR2趋化因子受体拮抗剂,RS 504393 是一种选择性的 CCR2 拮抗剂，作用于人重组 CCR2 和 CCR1 受体，IC50 值分别为 89 nM 和 > 100 μM。

生物活性	RS 504393 is a selective **CCR2** chemokine receptor antagonist (**IC_{50}** values are 89 nM and > 100 μM for inhibition of human recombinant CCR2 and CCR1 receptors respectively).
IC50 & Target[1][2]	CCR2: 89 nM (IC_{50}); Human α_{1a} receptor: 72 nM (IC_{50}); Human α_{1d} receptor: 460 nM (IC_{50}); 5HT-1a receptor: 1070 nM (IC_{50})

体外研究(In Vitro)	RS 504393 inhibits the MCP-1-induced chemotaxis with an IC_{50} of 330 nM. RS 504393 treatment suppresses allergen induced β-hexosaminidase release significantly. Without allergen priming, MCP-1 induces mast cell degranulation, which is completely suppressed by RS 504393. **Medlife has not independently confirmed the accuracy of these methods. They are for reference only.**
体内研究(In Vivo)	RS504393 (0.3-3 μg) with CCL2 progressively blocks thermal hyperalgesia dose-dependently in mice. RS 504393 (5 mg/kg, i.v.) supresses the elevated numbers of leukocytes and increased total protein content in BALF induced by The LPS. RS504393 significantly down regulates the LPS-induced elevation of IL-1β, PAI-1 mRNA and protein expressions. RS504393 significantly suppresses induced lung edema, protein-rich fluid, polymorphonuclear accumulation and bronchial wall thickening induced by LPS. RS-504393 significantly reduces renal pathology, especially the extensive interstitial fibrosis mediated by decrease in type I collagen synthesis in a UUO model. **Medlife has not independently confirmed the accuracy of these methods. They are for reference only.**
包装储存	Powder **-20°C** 3 years **4°C** 2 years In solvent **-80°C** 6 months **-20°C** 1 month

溶解度数据

体外研究:

DMSO : 12.5 mg/mL (**29.94 mM;** Need ultrasonic)

H_2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble)

配制储备溶液	溶剂体积 / 质量 / 浓度	1 mg	5 mg	10 mg
	1 mM	2.3952 mL	11.9760 mL	23.9521 mL
	5 mM	0.4790 mL	2.3952 mL	4.7904 mL
	10 mM	0.2395 mL	1.1976 mL	2.3952 mL

* 产品不同，其溶解度不同。建议根据产品选择合适的溶剂配制储备溶液；配成溶液后，**建议分装保存，避免反复冻融造成的产品失效**。

储备液的保存方式和期限： -80°C, 6 months; -20°C, 1 month。-80°C 储存时，建议在 6 个月内使用，-20°C 储存时，建议在 1 个月内使用。

体内研究:

建议根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都建议先按照 **体外研究** 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，**澄清的储备液可以根据储存条件，适当保存**；体内实验的工作液，**建议您现用现配，当天使用**； 以下溶剂前显示的百分比是指**该溶剂在您配制终溶液中的体积占比**；如在配制过程中出现沉淀、析出现象，可以通过**加热和/或超声的方式助溶**

1. 建议依照次序添加每种溶剂： 50% DMSO 15% EtOH 35% PEG300

   Solubility: 31.25 mg/mL (74.85 mM); Suspended solution; Need ultrasonic

2. 建议依照次序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline

   Solubility: ≥ 1.25 mg/mL (2.99 mM); Clear solution

   此方案可获得 ≥ 1.25 mg/mL (2.99 mM，饱和度未知) 的澄清溶液。

   以 1 mL 工作液为例，取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

   将 0.9 g 氯化钠，完全溶解于 100 mL ddH?O 中，得到澄清透明的生理盐水溶液

3. 建议依照次序添加每种溶剂： 10% DMSO 90% corn oil

   Solubility: ≥ 1.25 mg/mL (2.99 mM); Clear solution

   此方案可获得 ≥ 1.25 mg/mL (2.99 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

   以 1 mL 工作液为例，取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*